Renibus Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Texas, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
181 Grand Ave Ste 225, Southlake, Texas,...Phone Number
(682) 285-1711Website
www.renibus.comRevenue
$18.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Renibus Therapeutics
Renibus Therapeutics was found in 2016 and it is a clinical-stage biotech company dedicated to transforming the cardiorenal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company's portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, and RBT-3 for treatment of iron deficiency anemia and platinum-based kidney toxicity.Explore more
Renibus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Renibus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Renibus Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Renibus Therapeutics launches new products
Click to see if Renibus Therapeutics had a recent Job posting/layoffs
Check if Renibus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Renibus Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Renibus Therapeutics recently announced quarterly report
Check out if Renibus Therapeutics is spiking on competitors!
Renibus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Renibus Therapeutics
Find more new buyers
Compare Similar Companies to Renibus Therapeutics
Compare insights from companies similar to Renibus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Renibus Therapeutics
$18.3M
201-500
Private
$250.9M
2016
JK
Jeffrey KeyserPresident and CEO Renibus Therapeutics
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Renibus Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Renibus Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Renibus Therapeutics.
Renibus Therapeutics financials insights
Gather financial insights about Renibus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$35M
Debt
$33M
2023
Series B
$72M
2025
Private Equity
$110.9M
Renibus Therapeutics Tech Stack
A closer look at the technologies used by Renibus Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
, according to a recent Form D filing, has secured $110,895,239 in Private Equity funding.
Funding
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Renibus Therapeutics News & Media
Renibus Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference
SOUTHLAKE, Texas, Feb. 19, 2026 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation in the 36th Annual Oppenheimer Life Sciences...Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)
SOUTHLAKE, Texas, June 10, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare...Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)
- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, April 25, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage...Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce the Risk of Post-Operative Complications After Cardiac Surgery
- Topline results expected in Q3 2025 - SOUTHLAKE, Texas, April 24, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced the completion of...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Renibus Therapeutics
Sign Up For FreeTo access detailed company insights
Renibus Therapeutics was found in 2016 and it is a clinical-stage biotech company dedicated to transforming the cardiorenal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company's portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, and RBT-3 f... Read More
